Activist investor Starboard has taken a significant stake in Kenvue, leading to speculation about upcoming changes and adding pressure on Kenvue. There are concerns about the performance of Kenvue's skin health segment, with some analysts suggesting a need for significant overhaul. Despite this, Kenvue's stock value has seen an uptick, bolstered by the announcement of Starboard's investment and positive earnings guidance that exceeded estimates. The dividend payout of $0.205 has been affirmed. Analyst views on the stock seem mixed, with some raising their price target for Kenvue while others advocate for caution. Kenvue's quarterly results are set to be announced in early November, and its participation in the Barclays Global Consumer Staples Conference is on the cards. The company is making strides in its climate action strategy and has introduced patented micro-peptide technology through the launch of Neutrogena Collagen Bank.
Kenvue KVUE News Analytics from Tue, 07 May 2024 07:00:00 GMT to Sat, 26 Oct 2024 22:56:00 GMT -
Rating 7
- Innovation 3
- Rumor 0
